SELECT COUNTRY
VIEW ALL
AFRICA
AMERICAS
ASIA
EUROPE
OCEANIA
ALGERIA
ANGOLA
ARGENTINA
AUSTRALIA
AZERBAIJAN
BAHREIN
BELGIUM
BENIN
BOLIVIA
BOTSWANA
BRAZIL
BRUNEI
BURKINA FASO
CAMEROON
CANADA
CENTRAL AFRICAN REPUBLIC
CHAD
CHILE
CHINA
COLOMBIA
COTE D’IVOIRE
CZECH REPUBLIC
DOMINICAN REPUBLIC
DRC
ECUADOR
EGYPT
ETHIOPIA
FINLAND
FRANCE
GABON
GHANA
GREENLAND
GUINEA
HUNGARY
ICELAND
INDIA
INDONESIA
IRAN
IRAQ
ITALY
KAZAKHSTAN
KENYA
KUWAIT
LESOTHO
LIBERIA
MADAGASCAR
MALAWI
MALAYSIA
MALI
MAURITANIE
MEXICO
MONGOLIA
MOROCCO
MOZAMBIQUE
NAMIBIA
NETHERLANDS
NICARAGUA
NIGER
NIGERIA
NORWAY
PANAMA
PAPUA NEW GUINEA
PERU
PHILIPPINES
POLAND
QATAR
REPUBLIC OF CONGO
RUSSIA
RWANDA
SENEGAL
SIERRA LEONA
SINGAPORE
SLOVENIA
SOMALI
SOUTH AFRICA
SOUTH KOREA
SPAIN
SUDAN
SWEDEN
TAIWAN
TANZANIA
THAILAND
TOGO
TRINDAD & TOBAGO
TURKEY
TURKMENISTAN
UAE
UGANDA
UKRAINE
UNITED KINGDOM
UNITED STATES
VENEZUELA
VIETNAM
ZAMBIA
ZIMBABWE
UNITED STATES: LATEST INTERVIEWS MORE INTERVIEWS
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200 we have obtained orphan drug status from FDA for the treatment of liver cancer."
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."
UNITED STATES: LATEST ARTICLES
Protecting Supply Chains and Prosperity: The Case for Reducing US Dependency on Foreign Critical Minerals
October 12, 2022
Expert Opinion Article by Eric Mears, Vice President, Haley & Aldrich
Arizona Copper Production: Securing a Domestic Supply Chain
October 10, 2022
Arizona, leading the charge towards the green transition
Funding Environment: Life Sciences Enter the Mainstream
April 20, 2021
The past 12 months been transformative for the life science industry in USA, and GBR explores how the funding environment has evolved to provide the influx of capital to sustain its innovations.
UNITED STATES: RECENTLY RELEASED PUBLICATIONS
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
